International Classification of Sleep Disorders

New UK Survey Reveals Chronic Insomnia Impact Extends Beyond the Nighttime into The Following Day

Retrieved on: 
Thursday, October 27, 2022
DJ, Disorder, National Sleep Foundation, International Classification of Sleep Disorders, Male, SIX Swiss Exchange, Diagnosis, Life, Falls, ICSD, DSM5, Accident, Family, Patient, Quality of life, Population, American Academy of Sleep Medicine, Sleep, Education, Awareness, Knowledge Organization (journal), Ageing, Sleep medicine, IDIA, Friends, ISI, Parenting, Risk, American Psychiatric Association, Ipsos, Impact, List of Hindawi academic journals, Health, Diagnostic and Statistical Manual of Mental Disorders, Lists of diseases, Female, Adult, Consultant, Poultry, Medicine, Health insurance, Pharmaceutical industry, Fine chemical, Insomnia, Psychiatry

The survey reveals that chronic insomnia has a huge impact on a variety of aspects across people's lives during both the night and day.

Key Points: 
  • The survey reveals that chronic insomnia has a huge impact on a variety of aspects across people's lives during both the night and day.
  • These findings clearly highlight the significant impact that continued lack of sleep can have on many aspects of daily life.
  • For more information and resources on chronic insomnia, please visit Insomnia - The Sleep Charity .
  • The total score is interpreted as follows: sub-threshold insomnia (12-14), moderate clinical insomnia (15-21), and clinically severe insomnia (22-28).

NFL Player Speaks Out About Living With Narcolepsy; Partners with Project Sleep for World Narcolepsy Day

Retrieved on: 
Wednesday, September 22, 2021
Sleep paralysis, Social media, Sleep, Somnolence, Diagnosis, Muscle weakness, Atlanta Falcons, JD, Multimedia, International Classification of Sleep Disorders, Jack, NFL, 2008 Atlanta Falcons season, CEO, Awareness, View, Emotion, Stigma, Organization, Hallucination, Pharmaceutical industry

The third annual World Narcolepsy Day on Sept. 22, 2021 is co-led by 28 patient advocacy organizations across 6 continents, including new addition Narcolepsy China.

Key Points: 
  • The third annual World Narcolepsy Day on Sept. 22, 2021 is co-led by 28 patient advocacy organizations across 6 continents, including new addition Narcolepsy China.
  • The day unites the international narcolepsy community to inspire action, increase public knowledge, and elevate the voices of people living with narcolepsy worldwide.
  • To learn more about narcolepsy and be the first to know about Project Sleep's World Narcolepsy Day activities, visit the World Narcolepsy Day web page or follow along on social media using hashtag #WorldNarcolepsyDay.
  • Project Sleep is a 501(c)(3) non-profit organization dedicated to raising awareness about sleep health and sleep disorders.

David P. White, M.D. Appointed Senior Vice President of Medical Affairs at Apnimed

Retrieved on: 
Tuesday, July 27, 2021
Biotechnology, General Health, Medical devices, Health, Clinical trials, Sleep disorders, Branches of biology, Sleep apnea, Obstructive sleep apnea, Apnea, Sleep, Sleep medicine, International Classification of Sleep Disorders, Obstructive Sleep Apnea, Apnimed, OBSTRUCTIVE SLEEP APNEA, APNIMED

Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that David P. White, M.D., a world-renowned leader in sleep disorders has been appointed Senior Vice President of Medical Affairs.

Key Points: 
  • Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that David P. White, M.D., a world-renowned leader in sleep disorders has been appointed Senior Vice President of Medical Affairs.
  • Clinicians understand that obstructive sleep apnea is a prevalent and debilitating medical condition affecting the health and well-being of patients.
  • There is a tremendous unmet need for a safe, effective, and easy-to-use treatment option that addresses the underlying cause of the disease.
  • In addition to his new position at Apnimed, Dr. White is a Professor of Medicine, part-time, at Harvard Medical School in Boston, Mass.

Apnimed to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Tuesday, May 25, 2021
Medical devices, Other Health, Health, Pharmaceutical, Clinical trials, Sleep disorders, Branches of biology, Sleep, Obstructive sleep apnea, Sleep apnea, Sleep medicine, International Classification of Sleep Disorders

Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Companys management team will participate in the Jefferies Virtual Healthcare Conference, held June 1-4, 2021.

Key Points: 
  • Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Companys management team will participate in the Jefferies Virtual Healthcare Conference, held June 1-4, 2021.
  • Management will be available June 1st throughout the day for virtual one-on-one meetings.
  • Apnimed expects its pharmacologic therapies to transform treatment of this serious sleep disorder.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Apnimed Successfully Completes Phase 1 Study in Lead Program for Obstructive Sleep Apnea

Retrieved on: 
Thursday, September 17, 2020
Biotechnology, Other Health, Health, Pharmaceutical, Clinical trials, Sleep disorders, RTT, Branches of biology, Physiology, Health, Sleep apnea, Apnea, Obstructive sleep apnea, Oxybutynin, International Classification of Sleep Disorders, Infantile apnea, the study and results, AD109, Obstructive Sleep Apnea, Apnimed

Apnimed has successfully completed its first Phase 1 study with AD109 and Phase 2 clinical trials are planned for 4Q 2020.

Key Points: 
  • Apnimed has successfully completed its first Phase 1 study with AD109 and Phase 2 clinical trials are planned for 4Q 2020.
  • Proof of concept for the AD109 program was demonstrated in Apnimed study APN-002, a Phase 2, parallel group dose-finding study of the combination of atomoxetine and racemic oxybutynin.
  • Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea patients with Obstructive Sleep Apnea will benefit from treatment with a safe and effective oral medication.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Apnimed to Present at Oppenheimer’s Private Life Sciences Company Call Series

Retrieved on: 
Wednesday, August 12, 2020
Science, Other Science, Research, Pharmaceutical, Alternative medicine, Health, Clinical trials, Other Health, Sleep disorders, Branches of biology, Sleep, Physiology, Sleep apnea, Obstructive sleep apnea, Apnea, Sleep medicine, International Classification of Sleep Disorders, Obstructive Sleep Apnea, Apnimed

Apnimed, a clinical-stage pharmaceutical company focused on advancing medicines to treat sleep apnea and related disorders, today announced that the company will present at Oppenheimers Private Life Sciences Company Call Series, held virtually August 17-19, 2020.

Key Points: 
  • Apnimed, a clinical-stage pharmaceutical company focused on advancing medicines to treat sleep apnea and related disorders, today announced that the company will present at Oppenheimers Private Life Sciences Company Call Series, held virtually August 17-19, 2020.
  • The companys presentation is scheduled for Monday, August 17th from 9:15 AM 9:50 AM ET.
  • Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea patients with obstructive sleep apnea will benefit from treatment with a safe and effective oral medication.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Outlook on the Obstructive Sleep Apnea Global Market (2020 to 2024) - Develop Tactics and Strategies to Take Advantage of Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, July 10, 2020
General Health, Pharmaceutical, Health, Sleep disorders, Branches of biology, Animal physiology, Biology, Sleep apnea, Obstructive sleep apnea, Apnea, Sleep, International Classification of Sleep Disorders

This report provides comprehensive insights into the Obstructive Sleep Apnea pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.

Key Points: 
  • This report provides comprehensive insights into the Obstructive Sleep Apnea pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Obstructive Sleep Apnea market size and drug sales.
  • This research covers the following: Obstructive Sleep Apnea treatment options, Obstructive Sleep Apnea late stage clinical trials pipeline, Obstructive Sleep Apnea prevalence by countries, Obstructive Sleep Apnea market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Obstructive Sleep Apnea pipeline: Find out drugs in clinical trials for the treatment of Obstructive Sleep Apnea by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Obstructive Sleep Apnea drugs: Identify key drugs marketed and prescribed for Obstructive Sleep Apnea in the US, including trade name, molecule name, and company
    Obstructive Sleep Apnea drugs sales: Find out the sales value for Obstructive Sleep Apnea drugs by countries
    Obstructive Sleep Apnea market valuations: Find out the market size for Obstructive Sleep Apnea drugs in 2019 by countries.

Global Sleep Apnea Devices Market (2019 to 2026) - by Products, Application, End-users and Geography

Retrieved on: 
Wednesday, June 3, 2020
Sleep disorders, Branches of biology, Sleep, Medicine, Sleep apnea, Central sleep apnea, Obstructive sleep apnea, Apnea, International Classification of Sleep Disorders

The Sleep apnea devices global market is expected to grow at high single digit CAGR from 2019 to 2026 to reach $8,173.8 million by 2026.

Key Points: 
  • The Sleep apnea devices global market is expected to grow at high single digit CAGR from 2019 to 2026 to reach $8,173.8 million by 2026.
  • The sleep apnea diagnostic devices market is further classified into in-lab sleep test and home sleep test.
  • The sleep apnea application market is segmented into obstructive sleep apnea (OSA), central sleep apnea (CSA) and complex sleep apnea syndrome (ComSAS).
  • The Sleep apnea devices global market based on end-user is segmented into hospitals, sleep centers, home healthcare and others.

Sleep Aids Market Worth $114.15 Billion by 2025: Exclusive Report by Infinium Global Research

Retrieved on: 
Friday, May 15, 2020
Sleep disorders, RTT, Branches of biology, Psychiatric diagnosis, Neuroscience, Biology, Insomnia, Sleep, Narcolepsy, Classification of sleep disorders, International Classification of Sleep Disorders

PUNE, India, May 15, 2020 /PRNewswire/ -- A recent report by Infinium Global Research " Sleep Aids Market (By Product Mattress & Pillows, Sleep Laboratories, Medications and Sleep Apnea Devices; By Sleep Disorder Insomnia, Sleep Apnea, Restless Leg Syndrome, Narcolepsy, Sleep Walking and Other Sleep Disorders): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025."

Key Points: 
  • PUNE, India, May 15, 2020 /PRNewswire/ -- A recent report by Infinium Global Research " Sleep Aids Market (By Product Mattress & Pillows, Sleep Laboratories, Medications and Sleep Apnea Devices; By Sleep Disorder Insomnia, Sleep Apnea, Restless Leg Syndrome, Narcolepsy, Sleep Walking and Other Sleep Disorders): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025."
  • Download Exclusive Sample Copy of Report: https://www.infiniumglobalresearch.com/survey-reports/sample/6
    The report includes a detailed study on the consumer preference towards various products in the market.
  • Companies including Sanofi, GSK, and Pfizer hold a large share in the global sleep aids market.
  • In terms of geography, the North America region generated the highest revenue in the global sleep aids market in 2018.

Sleep Apnea Devices Market Report Forecasts USD 10 Billion Worth to 2025: Global Market Insights, Inc.

Retrieved on: 
Friday, September 27, 2019
Sleep disorders, Branches of biology, RTT, Neuroscience, Psychiatric diagnosis, Obstructive sleep apnea, Sleep apnea, Insomnia, Sleep, Apnea, International Classification of Sleep Disorders, Sleep medicine

Moreover, rise in geriatric and obese population susceptible to suffer from sleep apnea will further augment the demand for effective therapeutic and diagnostic sleep apnea devices in the upcoming years.

Key Points: 
  • Moreover, rise in geriatric and obese population susceptible to suffer from sleep apnea will further augment the demand for effective therapeutic and diagnostic sleep apnea devices in the upcoming years.
  • Global sleep apnea devices market is poised to reach over USD 10 billion by 2025 driven by increasing prevalence of sleep disorders as a major growth stimulating factor.
  • Favorable reimbursement scenario for diagnostic and therapeutic sleep apnea devices will increase the adoption rate of these devices in the future, thus escalating the therapeutic sleep apnea devices market growth.
  • Sleep Aids Market Forecasts 2019 2025: Growing incidence of sleep disorders such as chronic insomnia, obstructive sleep apnea, narcolepsy will stimulate global sleep aids business growth in the coming years.